抗beta Amyloid [Pyro Glu3]抗体 | Anti-beta Amyloid [Pyro Glu3] Antibody

• 価格
• Image
• Background

価格

目次に戻る

Image

	Western Blot: beta Amyloid [Pyro Glu3] Antibody [NBP1-44048] - Lane 1-10: beta Amyloid pyro E3 peptide. Load: 1 ug per lane 1-2, 0.2 ug per lane 3-4, 0.05 ug per lane 5-6, 0.01 ug per lane 7-8, 0.005 ug per lane 9-10. Primary antibody: Beta Amyloid pyro E3 antibody at 0.5 ug/mL for overnight at 4C. Secondary antibody: IRDye800 rabbit secondary antibody at 1:10,000 for 45 min at RT. Block: 5% BLOTTO overnight at 4C. Predicted/Observed size: 86.9 kDa for beta Amyloid pyro E3 peptide. Cross reactivity with Beta Amyloid 3 peptide is >1000 fold below pyrE3 reactivity and contains no reactivity towards the Beta Amyloid 42 A beta peptide (data not shown).
	Immunocytochemistry/Immunofluorescence: beta Amyloid [Pyro Glu3] Antibody [NBP1-44048] - Tissue: human brain section. Fixation: 0.5% PFA. Antigen retrieval: not required. Primary antibody: beta Amyloid pyro E3 antibody at 5 ug/mL for 1 h at RT. Secondary antibody: Rabbit secondary antibody at 1:10,000 for 45 min at RT. Localization: beta Amyloid pyro E3 is nuclear and cytoplasmic. Staining: Top: Beta Amyloid pyro E3 as as green fluorescent signal, Beta Amyloid 3 as yellow signal; and Bottom: Beta Amyloid 3 as red signal with co-incubation of Beta Amyloid pyro E3 peptide.
	Western Blot: beta Amyloid [Pyro Glu3] Antibody [NBP1-44048] - Lane 1: beta Amyloid 3 peptide Lane 2: beta Amyloid pyro E3 peptide. Load: 1 ug per lane. Primary antibody: Beta Amyloid pyro E3 antibody at 2ug/mL for overnight at 4C. Secondary antibody: IRDye800 rabbit secondary antibody at 1:10,000 for 45 min at RT. Block: 5% BLOTTO overnight at 4C. Predicted/Observed size: 86.9 kDa for beta Amyloid pyro E3 peptide.
	Immunocytochemistry/Immunofluorescence: beta Amyloid [Pyro Glu3] Antibody [NBP1-44048] - Laser scanning confocal microscopy was carried out using human tissue sections from frontal cortex. Figure A shows an example section that was immunostained for the presence of pyrE3Abeta (green). Figure B shows that the immunogen peptide completely blocked the NBP1-44048 antibody.

目次に戻る

Background

The cerebral and vascular plaques associated with Alzheimer's disease are mainly composed of Amyloid beta peptides. beta Amyloid is derived from cleavage of the Amyloid precursor protein and varies in length from 39 to 43 amino acids. beta Amyloid [1-40], beta Amyloid [1-42], and beta Amyloid [1-43] peptides result from cleavage of Amyloid precursor protein after residues 40, 42, and 43, respectively. The cleavage takes place by gamma-secretase during the last Amyloid precursor protein processing step. beta Amyloid [1-40], beta Amyloid [1-42], and beta Amyloid [1-43] peptides are major constituents of the plaques and tangles that occur in Alzheimer's disease. beta Amyloid antibodies and peptides have been developed as tools for elucidating the biology of Alzheimer's disease.

目次に戻る